Federal Register Notices
View Federal Register notices of proposed exclusive licenses. Clicking on the "View" links will display the Federal Register Notice in a new tab. You can also search directly on the Federal Register site.
| View | Date Published | Title | Comments Close On | Dates |
|---|---|---|---|---|
| View | Prospective Grant of Exclusive License: Compositions and Method for Preventing Reactogenicity Associated with Administration of Immunogenic Live Rotavirus Compositions | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before October 31, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Conjugate Vaccines Against B. anthracis (Anthrax) and Monoclonal Antibodies Against Anthrax | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before September 26, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Devices for Clearing Mucus From Endotracheal Tubes | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before September 23, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Use of PKM2 Activators for the Treatment of Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before September 7, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License; The Development of Ulipristal Acetate for the Treatment of Symptomatic Uterine Fibroids | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License; Devices for Clearing Mucus From Endotracheal Tubes | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before July 22, 2011 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Granting of an Exclusive License | 10/24/2005. | ||
| View | Prospective Grant of Exclusive License: Device and System for Two Dimensional Analysis of Biomolecules From Tissue and Other Samples | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before May 5, 2011 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before March 31, 2011 will be considered. | ||
| View | Cancer Therapy Evaluation Program Intellectual Property Option to Collaborator | |||
| View | Prospective Grant of Exclusive License: Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before February 11, 2011 will be considered. | ||
| View | Prospective Grant of Exclusive License: Devices for Treating Dysphagia and Dysphonia | Only written comments and/or applications for a license received by the NIH Office of Technology Transfer on or before January 6, 2011 will be considered. | ||
| View | Approval Pathway for Biosimilar and Interchangeable Biological Products; Public Hearing; Request for Comments | The public hearing will be held November 2 and 3, 2010, from 8:30 a.m. to 4:30 p.m. Individuals who wish to present at the public hearing must register on or before October 11, 2010. Section III of this document provides attendance and registration information. Electronic or written comments will be accepted after the public hearing until December 31, 2010. | ||
| View | Prospective Grant of Exclusive License: Prevention, Prophylaxis, Cure, Amelioration, and/or Treatment of Infection and/or the Effects Thereof of Chikungunya Infections in Humans | Only written comments and/or application for a license that are received by the NIH Office of Technology Transfer on or before October 25, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: The Development of Human Therapeutics for the Treatment of Cancer | Only written comments and/or applications for a license which are received by the NIH Office of Technology Transfer on or before August 3, 2010 will be considered. | ||
| View | Prospective Grant of Exclusive License: Development of Anti-Angiogenesis Cancer Therapeutics Targeting Adrenomedullin or Proadrenomedullin N-Terminal 20 Peptide (PAMP) | Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 30, 2009 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Prospective Grant of Exclusive License: Multi-Domain Amphipathic Helical Peptides for the Treatment of Cardiovascular Diseases | Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before March 30, 2009 will be considered. | ||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing | |||
| View | Government-Owned Inventions; Availability for Licensing |